Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer

Inclusion Criteria: * Provided signed written informed consent. * Men and woman age \> 18 years * Histologically confirmed R0 OR R1 resected ductal adenocarcinoma of the pancreas * Life expectancy \>12 weeks * Patients with performance status of ECOG ≤ 2 * Patients without metastasis Exclusion Criteria: * Women of child bearing potential (WOCP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and follow-up to 4 weeks after the study. * Women who are pregnant or breastfeeding. * Women with a positive pregnancy test on enrollment or prior to study drug administration. * Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent. * Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for \> 5 years will be allowed to enter the trial). * Inadequate hematologic function defined by an absolute neutrophils count (ANC) \< 1,500/mm³, a platelet count \< 100,000/mm³ and a hemoglobin \< 9 g/dL. * Inadequate hepatic function defined by the upper limit of normal (ULN), AST and ALT levels \> 5 times the ULN. * Serum bilirubin \> 1.5 times the ULN. * Inadequate renal function defined by a serum creatinine \> 1.5 times the ULN. * Prior cetuximab or other therapy that targets the EGF pathway. * Prior antibody therapy. * Any known allergic reaction against cetuximab. * Any concurrent chronic systemic immune therapy, radiation therapy, hormonal therapy (except for physiological replacement), or any other investigational agents. * HIV infection. * Having participated in another clinical trial in the preceding 30 days.